Tag Archive for: invizius

Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®

First patients treated with H-Guard® at the National Institute for Health and Care Research Manchester Clinical Research Facility MHRA approves continuation of Invizius’s first-in-human clinical study following a prearranged two-patient safety and performance review Study is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysis […]

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Invizius Limited (“Invizius”), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board. Read more…

Invizius announces ‘Angry Blood’ Haemodialysis Study and recruits its 300th patient

Novel study is investigating dysregulation of the complement system during standard hemodialysis therapy in relation to patient health outcomes Glasgow, Scotland, 13 June 2023 – Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has recruited its 300th patient […]

Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic

BioCity, Scotland, 30th March 2022  £1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of […]